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ABSTRACT

Cyano-substituted anthracene containing polyamines were
synthesized and shown to be efficient polyamine transporter
ligands. Moreover, these compounds (3 and 4) had improved
fluorescence properties over previously known anthrylpolyamine conjugates, which facilitated their intracellular
trafficking by confocal microscopy. These cytotoxic fluorescent agents may find use as molecular probes which traffic
into cells via the polyamine transport system and may also be
viable anticancer drugs which are readily quantified inhuman
tissues due to their excellent fluorescence properties: (excitation: A 405 nm) and emission (420 nm) occurs in the visible
light range. The ability to excite and emit in the visible range
provides an advantage to these probes as these wavelengths
are not toxic to human cells (versus ultraviolet mediated
excitations, "A.<400 nm) and visible light lasers are less costly
to purchase and operate than UV laser sources.
8 Claims, 6 Drawing Sheets
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FLUORESCENT CYTOTOXIC COMPOUNDS
SPECIFIC FOR THE CELLULAR
POLYAMINE TRANSPORT SYSTEM

disclosed fluorescent PAT pro bes to provide the unique ability
of tracking the drug into the cell by visualizing the fluorescent
tag.
After studying polyamine transport processes for many
years, we discovered and have previously disclosed compounds 1 and 2 as optimal polyamine transporter (PAT) selective agents (FIG.1). These compounds enter and kill cells via
their polyamine transport system. The polyamine transport
system is a measurable phenomenon but the genes and proteins involved are poorly understood. The instant invention
couples our earlier discovery of PAT selective agents 1 and 2
and modifies their structure to now provide compounds 3 and
4, which are highly fluorescent compounds useful for tracking polyamine uptake processes in mammalian systems (FIG.
1).
We have synthesized these fluorescent probes (compounds
3 and 4) and performed some confocal microscopy with compound 3 to illustrate this technology in action. An important
improvement over earlier systems is that even though compounds 1 and 2 are fluorescent they require excitation in the
ultraviolet range (393 nm) and emit in the visible range (410
nm). This requirement is detrimental to biological studies as
the UV radiation is injurious and can kill the exposed cells.
New compounds 3 and 4 contain a cyano group which
extends the compounds' pi system just enough that these
systems are now excited at 405 nm (blue light) and emit at 420
nm (in the visible light range). This improvement in their
photophysical properties coupled with their high selectivity
in entering cells via the PAT system make these compounds
valuable new tools for molecular and cell biologists interested
in tracking polyamine uptake phenomena via fluorescence
measurements or via confocal microscopy.
The present disclosure also contemplates that the invention
includes the compound of Formula 3 used in manufacturing a
pharmaceutical composition acceptable for administration to
a patient. Those skilled in the art should recognize that the
compounds of this invention may be administered to mammals, preferably humans, either alone or in combination with
pharmaceutically acceptable carriers, excipients or diluents,
in a pharmaceutical composition, according to standard pharmaceutical practice. The compounds can be administered by
any route but are preferably administered parenterally,
including by intravenous, intramuscular, intraperitoneal, subcutaneous, rectal and also by topical routes of administration.
The term "composition" is intended to encompass a product comprising the disclosed compounds in amounts effective
for causing the desired effect in the patient, as well as any
product which results, directly or indirectly, from combination of the specific ingredients. However, the skilled should
understand that when a composition according to this invention is administered to a human subject, the daily dosage of
active agents will normally be determined by the prescribing
physician with the dosage generally varying according to the
age, weight, sex and response of the individual patient, as well
as the severity of the patient's symptoms.
The terms pharmaceutical composition, pharmaceutically
and/or pharmacologically acceptable for administration to a
patient refer to molecular entities and/or compositions that do
not produce an adverse, allergic and/or other untoward reaction when administered to a subject, be it animal or human, as
appropriate. As known to the skilled, a pharmaceutically
acceptable composition or carrier includes any and/or all
solvents, dispersion media, coatings, antibacterial and/or

RELATED APPLICATION
This application claims priority from co-pending provisional application Ser. No. 60/166,889 which was filed on 6
Apr. 2009, and is also a continuation-in-part of application
Ser. No. 12/113,540 filed on 1 May 2008, both applications
being incorporated herein by reference in their entirety.

FIELD OF THE INVENTION
The present invention relates to the field of mammalian
cellular physiology and, more particularly, to fluorescent
molecules that are transported into a cell via the polyamine
transporter system.
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BACKGROUND OF THE INVENTION
25

Polyamines are organic compounds having at least two
primary amine groups, for example NH 2 . These compounds
have a role in the metabolism of mammalian cells but their
exact functions are not well described. It is known that cells
can synthesize polyamines and that, if cellular synthesis is
blocked, exogenously supplied polyamines may be imported
into the cell via the so called polyamine transporter system.
While it is known that polyamines are synthesized in cells
through highly-regulated pathways, their actual function has
not been fully elucidated.
They are known to bind to DNA as cations, and, in structure, they represent compounds with cations that are found at
regularly-spaced intervals (unlike, say, Mg++ or Ca++, which
are isolated point charges).
When synthesis of cellular polyamines is inhibited, the
cell's growth is stopped or severely inhibited. Adding exogenous polyamines reactivates the growth of these cells. Most
eukaryotic cells have a polyamine transporter system on their
cell membrane that facilitates the intake of exogenously provided polyamines. The polyamine transporter (PAT) system
is highly active in rapidly proliferating cells and is the target
of some chemotherapeutics currently under development.
Polyamines are also known to modulate a number of ion
channels, to enhance permeability of the blood-brain barrier
and to even regulate senescence in plants, thus being considered plant hormones. Since many cancer cell lines have active
polyamine transporters, it is possible to target these cells
using the molecular recognition events involved in polyamine
import.

SUMMARY OF THE INVENTION
With the foregoing in mind, the present invention advantageously provides novel fluorescent compounds that are rapidly internalized by a cell via the polyamine transporter system, thus providing easily tracked pro bes for the further study
of this transport mechanism. Consequently, it may be possible to attach a therapeutic drug moiety to the presently
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antifungal agents, isotonic and/or absorption delaying agents
and/or the like. The use of such media and/or agents for
pharmaceutical active substances is well known in the art.
Except insofar as any conventional media and/or agent is
incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active
ingredients can also be incorporated into the compositions.
For administration, preparations should meet sterility, pyrogenicity, general safety and/or purity standards as required by
FDA Office of Biologics standards. The skilled will find
additional guidance in preparation of pharmaceutically
acceptable compositions by consulting United States Pharmacopeia (USP) or other similar treatises employed in the
pharmaceutical industry.

FIG. 2 shows a fluorescence microscopy view of PAT inactive CHOMG cells treated with compound 3 (10 µM) after 4
hours;
FIG. 3 again shows a fluorescence microscopy view of
CHO wild type cells treated with compound 3 (10 µM) after
4 hours:
10

15

FIG. 4 illustrates a synthetic scheme for producing compound 3 (Reaction Scheme 1), wherein reagents are a) BuLi,
DMF, b) Pd(OAc) 2 /K4 [Fe(CN) 6 ], c) H2~CH 2 )4N(Boc)
(CH 2 ) 4 NHBoc, NaBH4 , and d) 4 N HCl;

FIG. 5 depicts a synthetic scheme for producing compound
4 (Reaction Scheme 2), wherein reagents employed are (a)
The present disclosure also contemplates a second comCuBr2 /t-BuONO; (b) NaBH4 , then 3M HCl; (c) vinylene
pound, of Formula 4 and related to the compound of Formula
carbonate, d) KOH/EtOH to give the dial, then Pb(OAc )4 ; ( e)
3 by both being derivatives of an anthracene compound. This
Pd(OAc)iK4 [Fe(CN) 6 ]; (f) H 2 N(CH 2 ) 4 N(Boc)(CH 2 ) 4 NHsecond compound is shown below according to Formula 4 20
Boe, NaBH4 , and (g) 4 N HCl; and
and salts thereof. The compound of Formula 4 has chemical
and biological properties that parallel those of the compound
FIG. 6 shows a line graph depicting the UV-VIS spectra of
of Formula 3 and may be employed in a likewise manner, as
Ant44 (compound 1) and cyanoAnt44 (compound 3) in PBS
described above.
25 buffer, 100 µMat 25° C.
As used herein, the terms "treat," "treating" or "method of
treatment" refer to both therapeutic treatment and prophylactic or preventive measures, wherein the object is to prevent or
DETAILED DESCRIPTION OF THE PREFERRED
slow down (lessen) an undesired physiological change or
EMBODIMENT
disorder, such as the development or spread of cancer or other 30
proliferation disorder. For purposes of this invention, benefiThe present invention will now be described more fully
hereinafter with reference to the accompanying drawings, in
cial or desired clinical results include, but are not limited to,
which preferred embodiments of the invention are shown.
alleviation of symptoms, diminishment of extent of disease,
stabilized (i.e., not worsening) state of disease, delay or slow- 35 Unless otherwise defined, all technical and scientific terms
used herein have the same meaning as commonly understood
ing of disease progression, amelioration or palliation of the
by one of ordinary skill in the art to which this invention
disease state, and remission (whether partial or total),
pertains. Although methods and materials similar or equivawhether detectable or undetectable. For example, treatment
lent to those described herein can be used in the practice or
with a compound of the invention may include reduction of
testing
of the present invention, suitable methods and mateundesirable cell proliferation, and/or induction of apoptosis 40
rials are described below. Any publications, patent applicaand cytotoxicity. "Treatment" can also mean prolonging surtions, patents, and other references mentioned herein are
vival as compared to expected survival if not receiving treatincorporated by reference in their entirety. In case of conflict,
ment.
the present specification, including any definitions, will conThe terms "effective to inhibit" or "growth inhibitory 45 trol. In addition, the materials, methods and examples given
amount" of the compounds of the invention refer to an amount
are illustrative in nature only and not intended to be limiting.
which reduces (i.e., slows to some extent and preferably
Accordingly, this invention may be embodied in many different forms and should not be construed as limited to the illusstops) proliferation of a target cell, such as a tumor cell, either
trated embodiments set forth herein. Rather, these illustrated
in vitro or in vivo, irrespective of the mechanism by which
cell growth is inhibited (e.g., by cytostatic properties, cyto- 50 embodiments are provided so that this disclosure will be
thorough and complete, and will fully convey the scope of the
toxic properties, etc.).
invention to those skilled in the art. Other features and advantages of the invention will be apparent from the following
detailed description, and from the claims.
55
U.S. patent application Ser. No. 12/113,540 was filed on 1
BRIEF DESCRIPTION OF THE DRAWINGS
May 2008 and application Ser. No. 12/113,970 was filed on 2
May 2008. These two applications disclosed other polyamine
Some of the features, advantages, and benefits of the
compounds
related to and having similar biological properpresent invention having been stated, others will become
60 ties to the presently disclosed compounds 3 and 4. Accordapparent as the description proceeds when taken in conjuncingly, these two patent applications are incorporated herein
tion with the accompanying drawings, presented for solely
by reference in their entireties.
for exemplary purposes and not with intent to limit the invenIn the present disclosure, using Chinese hamster ovary
tion thereto, and in which:
(CHO) cells as a test cell line, we have shown that compound
FIG. 1 provides the formulas for previously known com- 65 3 is significantly more toxic to wild-type CHO cells than to
pounds 1-2, as well as presently disclosed novel compounds
their CHO MG mutant, which is defective in polyamine transport. Since these compounds use the PAT for cellular entry,
3-4 according to an embodiment of the present invention;
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they are very toxic to cell lines containing active polyamine
transporters (e.g., CHO cells) but less so to cell lines with
defects in this pathway (CHOMG).

TABLE 1

As known to those skilled in the art, the IC 50 is the concentration of the drug required to kill 50% of the relative cell
population. That is, the lower the IC 50 , the more potent the
drug. See Table 1. We employed confocal microscopy to look
at the cell localization behavior of compound 3 in these two
cell lines at different time points.
FIG. 2 shows inactive CHOMG cells treated with compound 3 (10 uM), the fluorescence microscopy view being
taken after the cells had been exposed to the compound for 4
hrs. Compound 3 is mainly sequestered in intracellular
vesicles at the 4 hr incubation time-point (FIG. 2). The
CHOMG mutant defect seems to block vesicular escape of
the probe. Note that the fluorescent probe, compound 3,
appears as a blue dot (right image) as it remains localized
within vesicles. The green image (left image) is acquired from
an actin-binding stain to show the cells' cytoskeletal architecture surrounding the blue probe 3.
In FIG. 3 PAT active CHO wild type cells are shown after
being treated with compound 3 (10 uM) for 4 hrs. In contrast
to CHO MG, shown in FIG. 2, the wild type CHO cells shown
in FIG. 3 allow compound 3 to escape the vesicle compartments and arrive at the perinuclear compartment after 4 hrs. of
incubation. This is clearly seen as the 'blue halo' effect. Note
that the fluorescent drug, compound 3, appears as a blue
image. The green image is taken with an actin-binding stain to
show the cells' cytoskeletal architecture.
The skilled will recognize that the CHOMG/CHO IC 50
ratio is indicative of PAT selectivity. As seen in Table 1,
control compound 5 (a water soluble anthracene derivative
with the incorrect message to utilize the polyamine transporter, PAT) gave the same IC 50 value in both the CHO and
CHOMG cell lines. i.e. the CHOMG/CHO IC 50 ratio=!.
Therefore, the control compound 5 had no selectivity for
targeting cells with the active PAT. In contrast, the smart
polyamine probes 1-4 all showed greater toxicity to the CHO
cell line over its CHO MG mutant (IC50ratios>>1). In addition, the L1210 cells (murine leukemia cells) were more
sensitive (lower IC 50 values) to the smart probes 1-4 than the
control 5. These cells also gave lower K, values, which is
indicative of greater binding to the PAT. In contrast the control
5 gave a significantly higher K, value (32.2 µM).
A comparison of the UV-visible absorbance spectra of the
Ant44 (compound 1) and cyanoAnt44 (compound 3) derivatives (FIG. 6) shows a shift to longer wavelength (red shift) of
the absorbance spectrum upon cyanation of the ring. The
extended pi system is responsible for this shift to 409 nm and
was part of the design process in constructing the cyano
derivative.
An important reason for using >400 nm for polyamine
probe excitation is that one can use a visible light laser, for
example a blue laser, to excite the compound at 405 nm. In
contrast, exciting probes of wavelength below 400 nm would
require a very costly UV laser, which are also expensive to
maintain and to cool during operation.
In addition, UV excitation has other problems since other
biofluorophores such as DNA bases, tryptophan, etc., can be
excited by UV radiation. Accordingly, in order to distinguish
the presently disclosed polyamine probes it was advantageous to be able to use excitation

Biological Evaluation of polyamine
derivatives in CHO and CHO-MG cells
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30

H

N~NH2
35
3HC1
5: Fl, y=4
40

Compd (tether)
l:Ant-4,4
45
2: 4,4-Ant-4,4
3: cyano-Ant-4,4
4: cyano-4,450 Ant-4,4
5:Ant-4
(control)

CHOMG
ICso
inµM
66.7
(±4.1)
>100

CHO
ICso
inµM

48.7
(±1.6)
ND

0.45
(±0.10)
0.045
(±0.003)
0.96
(±0.01)
ND

7.6
(±0.4)

7.7
(±0.5)

(CHOMG/CHO)
IC so
Ratiob
148
>2222
51
ND

L1210
K,
value
inµM

L1210
ICso
value
inµM

1.8
(±0.1)
0.39
(±0.05)
3.8
(±0.28)
ND

0.3
(±0.1)
0.78
(±0.07)
0.31
(±0.01)
ND

32.2
(±4.3)

6.3
(±0.3)

acells were incubated for 48 h with the respective conjugate, Ant= anthrylmethyl;
ba measure of PAT selectivity, not determined

55

60

65

frequencies in the visible light region. We accomplished this
by making the cyano derivatives which have an absorption
band near 409 nm in PBS (see FIG. 6).
Materials and Methods
Control compounds 1, 2, and 5 were synthesized previously. REF: (a) "Synthesis and Biological Evaluation ofN 1 (anthracen-9-ylmethyl)triamines as Molecular Recognition
Elements forthe Polyamine Transporter," Wang, C.: Delcros,
J-G.; Biggerstaff, J.; Phanstiel IV, 0. J. Med. Chem. 2003, 46,
2663-2671; (b) A Comparison of Chloroambucil- and
Xylene-containing polyamines leads to improved ligands for
accessing the polyamine transporter. Navneet Kaur, Jean-
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Guy Delcros, and Otto Phanstiel IV. J. Med. Chem. 2008, 51,
1393-1401; (c) "N'-Substituent Effects in the Selective Delivery of Polyamine-Conjugates into Cells Containing Active
Polyamine Transporters" Gardner, R. A.; Delcros, J-G.;
Konate, Breitbeil III, F.; Martin, B.; Sigman, M.; Huang, M.;
Phanstiel IV, 0. J. Med. Chem. 2004, 47, 6055-6069.)
10-( (4-( 4-amino butylamino) buty!amino )methyl )anthracene-9-carbonitrile (3):
The diBOC amine 8 (0.15 mmol) was dissolved in EtOH (3
mL) and cooled to 0° C. 4N HCI (6 mL) was added dropwise
at 0° C. The solution was stirred at it overnight. The solution
was concentrated under reduced pressure to give a yellow
solid 3 in 96% yield. 1H NMR (300 MHz. D 20): ll 8.18 (d,
2H), 8.00 (d, 2H), 7.73 (m, 4H), 5.06 (s, 2H), 3.25 (t, 2H), 3.06
(m, 6H), 1.75 (m, SH). d HRMS: theory for C 24H 30N 43HCI:
375.2543.
found
375.2553.
Anal.
calcd
for
C 24H 33 N 4Cl 30.2H 20: C, 59.13; H, 6.91; N, 11.49. Found: C,
59.21; H, 7.01; N, 11.54.
9-Bromo- l 0-anthracenecarboxaldehyde ( 6):
To the yellow suspension of 9, 10-Dibromoanthracene (2 g,
5.95 mmol) in THF (20 mL) at -90° C., n-BuLi (2.88 mL,
7.18 mmol, 2.5 Min hexane) was added dropwise. Orange
solution was observed after 45 min additional stirring. Anhydrous DMF (0.92 mL, 11.9 mmol) was added to the orange
solution. The reaction mixture was slowly warmed to room
temp and stirred overnight. The reaction mixture was
quenched with H 20 and extracted with CH 2Cl 2. The organic
layer was washed with 10% aq. Na 2C0 3 solution (3x50 mL).
The CH 2Cl 2 layer was separated, dried over anhydrous
Na 2S04, filtered and removed in vacuo to give yellow solid.
The crude product was purified by colunm chromatography
using 30% CH 2Clihexane to give 6 in 68% yield. Rf=0.3
(30% CH 2Cl 2/hexane; 1H NMR (CDCl 3) d 11.39 (s, lH),
8.77-8.82 (d, 2H), 8.55-8.60 (d, 2H), 7 .56-7 .67 (m, 4H). (Ref.
de Montigny, Frederic; Argouarch, Gilles; Lapinte, Claude.
New route to unsymmetrical 9,10-disubstituted ethynylanthracene derivatives. Synthesis, 2006, 2, 293-298.)
9-Cyano- l 0-anthraldehyde (7):
9-Bromo- l 0-anthracenecarboxaldehyde (200 mg, 0. 7
mmol) was heated with copper (I) cyanide (75.4 mg, 0.84
mmol) and pyridine (3 mL) for 12 hr at 230° C. After cooling,
the mixture was washed with dilute NH40H and ether. The
ether extract was washed with water, IN HCI, again water,
dried over anhydrous Na2S04, filtered and removed in vacuo
to give yellow solid, which was purified using colunm chromatography using 40% CH 2Cl 2/hexane in 40% yield. 1H
NMR (CDCl 3) ll 11.43 (s, lH), 8.72-8.77 (d, 2H), 8.44-8.49
(d, 2H), 7.71-7.77 (m, 4H); 13 C NMR (CDCl3) ll 193.4,
160.8, 129.9, 129.4, 129.0, 126.3, 124.4. (Ref. Gore, P.H.;
Gupta, S. D.; Obaji, G. A. Anomalous reactions of cyanide
with two hindered aromatic aldehydes. Journal fuer Praktische Chemie (Leipzig). 1984, 326, 381-4.)
Optimized Procedure:
DMAC (N,N-dimethylacetamide) was used as a solvent.
As reaction is oxygen sensitive, DMAC was placed in three
necked round bottom flask with three way stopcock with
vacuum line in one side and ultra dry N 2 balloon on the other
side. Evacuation of the flask was done and DMAC was kept
under N 2 environment. To three necked flask Bromoaldehyde
6 (25 mg, 0.088 mmol), Zn(CN) 2 (18.5 mg, 0.157 mmol),
Pd2(dba) 3 (2.09 mg, 0.002 mmol), Zn dust (1 mg, 0.022
mmol) were weighed out and flask was evacuated and N 2 was
allowed to enter the flask via three way stopcock. DMAC (4
mL) was added to the flask via a syringe keeping the flask
under vacuum. t-Butyl phosphine (1.77 mg, 0.009 mmol) was
added via syringe. The whole assembly was transferred in an

oil bath at 80° C. and let the reaction stir at 80° C. for three
hours. After monitoring the consumption of 6 by TLC (40%
CH 2CliHexane), EtOAc (20 mL) was added to the reaction
mixture and crude reaction mixture was washed with saturated solution ofK2C0 3, organic layer was again washed with
saturated solution ofNH4Cl. The EtOAc layer was dried over
anhydrous Na2S04, filtered and removed in vacuo to give
yellow solid 7 in 89% yield by NMR.
(4-tert-Butoxycarbonylamino-butyl)-{ 4-[ (10-cyano-anthracen-9-ylmethyl)-amino ]-butyl}-carbamic acid tert-butyl
ester (8):
To a stirred solution ofN 1,N5 -di-Boe homospermidine (92
mg, 0.26 mmol) in 25% MeOH/CH 2Cl 2 (10 mL), was added
a solution of 9-Cyano-10-anthraldehyde 7 (49 mg, 0.21
mmol) in 25% MeOH/CH 2Cl 2 (10 mL) under N 2. The mixture was stirred at room temperature overnight until the imine
formation was complete (monitored by NMR). The solvent
was removed in vacuo, the solid residue dissolved in 50%
MeOH/CH 2Cl 2 (20 mL) and the solution cooled to 0° C.
NaCNBH 3 (0.25 mmol) was added in small portions to the
solution and the mixture was stirred at it overnight. The
solvent was removed in vacuo, the solid residue dissolved in
CH 2Cl 2 (30 mL) and washed with Na2C0 3 solution (10% aq.
3x30 mL). The CH 2Cl 2 layer was dried over anhydrous
Na 2S04, filtered and removed in vacuo to give an oily residue.
The oil was purified by flash column chromatography (1.5%
MeOH/CH 2Cl 2) to yield the product as a pale yellow solid (93
mg, 73%), Rf=0.23 (3% MeOH/0.5% NH40H/CH 2Cl 2); 1H
NMR (300 MHz, CDCl 3) ll 8.38 (m, 4H), 7.64 (m, 4H), 4.70
(s, 2H), 3.12 (m, 6H), 2.89 (m, 2H), 1.41-1.56 (m, 26H): 13 C
NMR: ll 156.0, 155.6, 139.1, 133.1, 129.6, 128.5, 127.0,
126.2, 125.1, 117.5, 79.4, 53.7, 50.6, 46.9, 46.1, 40.4, 28.7,
27.7, 26.1. HRMS (FAB)m/zcalcd. forC 34 H46 N 40 4 (M+Ht
575.3592.
found
575.3591.
Anal.
calcd
for
C 34 H46N 40 4.1H20: C, 68.89; H, 8.16; N, 9.45. Found: C,
68.77; H, 8.02; N, 9.42.
2-Bromoanthraquinone (10):
Copper (II) bromide (35.0 g, 0.157 mo!, 3.76 equiv.) was
dissolved in freshly-distilled acetonitrile (200 mL) at room
temperature to form an opaque dark-green solution. tert-Butyl nitrite (15 mL, 12.9 g, 0.125 mo!, 1.49 equiv.) was added
at 0° C. and stirred for 30 minutes at 0° C. 2-Aminoanthraquinone 9 (18.60 g, 0.0834 mo!, 1 equiv.) was dissolved in
tetrahydrofuran (THF, 300 mL) at room temperature to form
an opaque red-brown solution. The 2-aminoanthraquinone 9
solution was quickly added to the copper (II) bromide solution at 0° C. and the solution was stirred for 2 hours at 0° C.
with venting of the nitrogen gas by-product every 5 minutes
until the bubbling ceased. The consumption of 2-aminoanthraquinone 9 was monitored by thin-layer chromatography
(100% CHCl 3, Rf=0.32). Once the 2-aminoanthraquinone 9
was consumed, the THF and acetonitrile solvents were
removed from the mixture via rotary evaporation to give a
brown and black solid residue. The solid was rinsed with
deionized water to form a suspension. The resulting slurry
was vacuum filtered and rinsed with deionized water. The
filtration receiving flask was changed and the solid was
washed with CH 2Cl 2 through the filter paper, leaving a redbrown solid by-product and forming a yellow-brown solution. The CH 2Cl 2 was removed from the solution via rotary
evaporation, leaving a yellow solid consisting of the product
2-bromoanthraquinone 10 and by-product anthraquinone.
The desired product was separated and purified from the
unwanted by-product through colunm chromatography (35%
CHCl 3/hexane, Rf=0.33 and Rf=0.28 respectively), providing
2-bromoanthraquinone 10 as a light yellow solid (11.2 g;
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37%). 1 H NMR (CDCl 3 ): ll 8.42 (d, lH), 8.30 (m, 2H), 8.16
(d, lH), 7.91 (dd, lH), 7.80 (m, 2H).
2-Bromoanthracene (11 ):
2-Bromoanthraquinone 10 (8.50 g, 0.0296 mo!, 1 equiv)
and a 50:50 mixture ofisopropyl alcohol and tetrahydrofuran
(200 mL) were stirred for 10 minutes at 0° C. forming a
yellow suspension. NaBH4 (6.70 g, 0.177 mo!, 6.0 equiv.) was
added to the suspension at 0° C. The mixture was stirred at 0°
C. for three hours, turning red in color. The solution was then
warmed to room temperature. Additional NaBH4 (3.35 g,
0.089 mo!, 3.0 equiv.) was added to the solution at room
temperature and the solution was stirred at room temperature
for 12 hours, turning into an orange suspension. Deionized
water (10 mL) was added to the solution at room temperature
and the solution was stirred at room temperature for an additional 12 hours. The consumption of2-bromoanthraquinone
10 was monitored by thin-layer chromatography (35%
CHCl 3 /hexane, Rf=0.33). Once the consumption of 2-bromoanthraquinone 10 stopped entirely (it was never fully consumed), the volatiles were removed by rotary evaporation. 3
M HCI was slowly added to the solution until bubbling
ceased, then additional 3 M HCI (30 mL) was added. The
solution was heated at reflux for 6 hours, turning into an
opaque, yellow suspension in the process. The mixture was
cooled to room temperature, turning into a transparent solution containing yellow-brown crystals. The contents underwent rotary evaporation as much water as possible. The contents were then vacuum-filtered and washed using deionized
water to remove any water, acid and ionic salt, leaving behind
a yellow-brown colored solid. The vacuum-filtration receiving flask was changed and the solid was washed with CH 2 Cl 2
through the filter paper. The CH 2 Cl 2 was removed through
rotary evaporation. The remaining solid was purified through
colunm chromatography (100% hexane, Rf=0.27), providing
2-bromoanthracene 11 as a white, powdery solid (2.00 g,
26%). 1 HNMR(CDCl 3 ): ll 8.42 (s, lH), 8.34 (s, lH), 8.18 (d,
lH), 8.01 (m, 2H), 7.87 (d, lH), 7.50 (m, 3H).
2-Bromo-9, 1O-dihydro-9,1O-ethanoanthracene-11,12diol cyclic carbonate (12):
2-Bromoanthracene 11 (2.05 g, 8.0 mmol, 1 equiv.) and
vinylene carbonate (3.68 mL, 5.00 g, 58 mmol, 7.3 equiv.)
were heated under reflux with stirring for 18 hours, slowly
forming a dark brown solution. The consumption of 11 was
monitored by thin-layer chromatography (2% CH 2 Cl 2 /hexane, Rf=0.31). The mixture underwent rotary evaporation
under high vacuum to remove the excess vinylene carbonate,
providing the cyclic carbonate intermediate 12 as a lightbrown solid (2.74 g, >99%). 1 H NMR (CDCl 3 ): ll 7.52 (dd,
lH), 7.37 (m, 3H), 7.27 (m, 3H), 4.88 (m, 2H), 4.66 (m, 2H).
2-Bromo-9, 1O-dihydro-9,1O-ethanoanthracene-11,12dial (12a):
Solid potassium hydroxide (1.80 g, 32.0 mmol, 4 equiv.),
deionized water (30 mL ), and absolute ethanol (3 .2 mL) were
added to the light-brown cyclic carbonate intermediate 12
(2.74 g, 8.0 mmol, 1 equiv.). The solution was stirredat75° C.
for 3 hours. The consumption of the cyclic carbonate intermediate 12 was monitored through thin-layer chromatography (100% CH 2 Cl 2 , Rf=0.30). Afterwards, the solution
underwent rotary evaporation under reduced pressure to
remove the ethanol and roughly half of the water volume.
Additional water (60 mL) was added to the solution and the
solution was stirred at room temperature for one hour, resulting in the formation of light-tan solid. The contents were
vacuum-filtered and then washed with deionized water. The
vacuum-filtration receiving flask was changed and the solid
was washed with ethyl acetate through the filter paper. The
ethyl acetate was removed through rotary evaporation, leav-

ing a white solid residue. The product was purified through
colunm chromatography (90% CH 2 Cl 2 /ethyl acetate,
Rf=0.30 & Rf=0.15), providing two isomers of dial intermediate 12a as a white solid (2.01 g, 79%). 1 HNMR (CDCl 3 ): ll
7.52 (d, lH), 7.35 (dd, lH), 7.31(dd,2H), 7.25 (d, lH), 7.17
(dd, 2H), 4.40 (dd, 2H), 4.07 (m, 2H). 1 H NMR (CDCl 3 ): ll
7.45 (d, lH), 7.34 (dd, 2H), 7.27 (dd, lH), 7.20 (dd, 2H), 7.16
(d, lH), 4.35 (dd, 2H), 4.05 (d, 2H).
2-Bromo-9, 10-anthracenedialdehyde (13 ):
Dial intermediate 12a (1.58 g, 5.0 mmol, 1 equiv.) was
dissolved in anhydrous acetonitrile (100 mL) and heated to
reflux with stirring and formed a transparent, light-tan solution. Lead tetraacetate (4.42 g, 10.0 mmol, 2 equiv.) was
added portion-wise to the solution over a period of 5 minutes
quickly turning the solution opaque and brown in color. The
solution was then stirred at reflux for 4 hours, resulting in the
formation of a dark-orange precipitate within the brown solution. The consumption of the dial intermediates were monitored through thin-layer chromatography (80% CH 2 Cliethyl
acetate, Rf=0.50 & Rf=0.33).Afterthereaction was complete,
the reaction mixture was concentrated via rotary evaporation
and gave a burgundy residue. 10% aqueous sodium carbonate
(300 mL) was added to the residue, allowing the residue to be
suspended in the aqueous solution. The organic contents were
extracted from the aqueous layer using dichloromethane. The
opaque, yellow organic layer was dried over anhydrous
sodium sulfate, filtered, and concentrated to give a yelloworange solid residue. The residue was purified by colunm
chromatography (20% ethyl acetate/hexane, Rf=0.29), providing 2-bromo-9, 10-anthracenedialdehyde 13 as an orange
solid (1.23 g, 80%). 1 H NMR (CDCl 3 ): 11.43 (s, lH), 11.42
(s, lH), 9.03 (s, lH), 8.72 (m, 2H), 8.66 (d, lH), 7.75 (m, 3H).
Advantages of the Present Invention Over Prior Technology.
The novelty or improvement on the earlier systems is that
even though compounds 1 and 2 are fluorescent they require
excitation in the ultraviolet range (393 nm) and emit in the
visible range (410 nm). This requirement is detrimental to
biological studies as the UV radiation uses expensive UV
lasers, which are costly to maintain and cocl during operation.
The new compounds 3 and 4 contain a cyano group which
extends the compounds' pi system just enough that these
systems are now excited at 405 nm (blue light) and emit at 420
nm (in the visible light range). This improvement in their
photophysical properties coupled with their high selectivity
in entering cells via the polyamine transport system make
these valuable new tools for molecular biologist and cell
biologists interested in tracking polyamine uptake phenomena via fluorescence measurements or via confocal microscopy.
While there are numerous biological stains for tracking or
labeling cellular organelles, there are no commercial stains or
fluorescent agents that specifically enter and traffic through
the cell membrane via the polyamine transport system. The
novel compounds herein disclosed can be used to study
polyamine transport processes in living cells and to track
potential therapeutic agents tagged thereon. Accordingly,
advantages of the disclosed compounds include their special
PAT targeting ability and their desirable photophysical properties.
These compounds, as cellular stains, are further useful
added to cancer cells to track how the cancers are trafficking
their polyamine growth factors. These agents may also serve
as trackable anticancer drug candidates as they are cell selective for active PATs and are cytotoxic at µM concentrations.
As shown in FIGS. 2 and 3, the probes are able to discern
between PAT-active and PAT-inactive cell lines (blue halo vs
dots, respectively).
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Prior to the present disclosure there were no commercial
stains or fluorescent agents that specifically enter cells and
traffic through the polyamine transport system. This is likely
a multi-step process and is likely a time dependent phenomenon. We see an initial sequestration of compound 3 into
vesicles followed by escape to reach the perinuclear compartment.
Accordingly, in the drawings and specification there have
been disclosed typical preferred embodiments of the invention and although specific terms may have been employed, the
terms are used in a descriptive sense only and not for purposes
of limitation. The invention has been described in considerable detail with specific reference to these illustrated embodiments. It will be apparent, however, that various modifications and changes can be made within the spirit and scope of
the invention as described in the foregoing specification and
as defined in the appended claims.
That which is claimed:
1. A fluorescent cyano-substituted anthracene polyamine
compound according to formula 3

2. The compound of claim 1 used in manufacturing a pharmaceutically acceptable composition.
3. The compound of claim 1 used in a method of treatment
by being administered to a patient.
4. The compound of claim 1 used in a method of treatment
by being administered to a patient in an amount effective to
inhibit a cancer cell.
5. A fluorescent derivative of the compound of claim 1, the
derivative according to formula 4
10
Formula4
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Formula 3
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6. The compound of claim 5 used in manufacturing a pharmaceutically acceptable composition.
7. The compound of claim 5 used in a method of treatment
by being administered to a patient.
8. The compound of claim 5 used in a method of treatment
by being administered to a patient in an amount effective to
inhibit a cancer cell.
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